• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

作者信息

Edwards Camille V, Gould Julia, Langer Arielle L, Mapara Markus, Radhakrishnan Jai, Maurer Mathew S, Raza Shahzad, Mears John G, Wall Jonathan, Solomon Alan, Lentzsch Suzanne

机构信息

a Department of Medicine , Harlem Hospital Center , New York , NY , USA.

b Division of Hematology/Oncology , Columbia University Medical Center , New York , NY , USA.

出版信息

Amyloid. 2017 Mar;24(sup1):58-59. doi: 10.1080/13506129.2017.1292900.

DOI:10.1080/13506129.2017.1292900
PMID:28434347
Abstract
摘要

相似文献

1
Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.嵌合原纤维反应性单克隆抗体11-1F4治疗AL淀粉样变性患者的1a/b期研究的中期分析。
Amyloid. 2017 Mar;24(sup1):58-59. doi: 10.1080/13506129.2017.1292900.
2
One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.嵌合性原纤维反应性单克隆抗体11-1F4用于治疗AL淀粉样变性患者的1a/b期研究的一年随访分析。
Amyloid. 2019;26(sup1):115-116. doi: 10.1080/13506129.2019.1584892.
3
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.CAEL-101（11-1F4）单克隆抗体治疗淀粉样变病的 1a/b 期研究。
Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039.
4
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.在接受过大量预处理的 AL 淀粉样变性患者中使用达雷妥尤单抗进行治疗。
Leukemia. 2019 Feb;33(2):531-536. doi: 10.1038/s41375-018-0262-2. Epub 2018 Sep 28.
5
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.接受淀粉样蛋白定向单克隆抗体NEOD001治疗的AL淀粉样变性患者的器官反应
Am J Hematol. 2016 Dec;91(12):E506-E508. doi: 10.1002/ajh.24563. Epub 2016 Oct 21.
6
Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.单克隆抗体疗法在系统性轻链淀粉样变性中的应用。
Hematol Oncol Clin North Am. 2020 Dec;34(6):1145-1159. doi: 10.1016/j.hoc.2020.08.005. Epub 2020 Oct 3.
7
Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.纤维导向治疗系统性轻链淀粉样变。
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):555-559. doi: 10.1016/j.clml.2019.03.029. Epub 2019 Apr 1.
8
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.在复发的淀粉样变多发性骨髓瘤中使用达雷妥尤单抗的安全性、耐受性和应答率：一项 2 期研究的结果。
Blood. 2020 Apr 30;135(18):1541-1547. doi: 10.1182/blood.2019004436.
9
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.达雷妥尤单抗治疗2例晚期免疫球蛋白轻链淀粉样变性的安全性和有效性的首例报告。
Blood. 2016 Oct 13;128(15):1987-1989. doi: 10.1182/blood-2016-06-722496. Epub 2016 Aug 19.
10
Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody.使用一种与原纤维反应性单克隆抗体对轻链淀粉样蛋白进行放射性成像。
J Nucl Med. 2006 Dec;47(12):2016-24.

引用本文的文献

1
Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation.用于淀粉样变性的蛋白水解治疗方法：对免疫疗法、PROTAC和光氧化的见解。
Neurotherapeutics. 2025 Apr;22(3):e00548. doi: 10.1016/j.neurot.2025.e00548. Epub 2025 Feb 11.
2
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.改良梅奥Ⅲa期和Ⅲb期心脏轻链型淀粉样变的预后：67例患者临床特征与治疗的多中心真实世界经验分析
Cancers (Basel). 2024 Apr 21;16(8):1592. doi: 10.3390/cancers16081592.
3
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.
肾AL型淀粉样变性：诊断、分期及管理的最新进展
J Clin Med. 2024 Mar 18;13(6):1744. doi: 10.3390/jcm13061744.
4
Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion.一种原型泛淀粉样蛋白清除剂的开发和特性研究——一种新型的鼠源肽-免疫球蛋白融合物。
Front Immunol. 2023 Oct 2;14:1275372. doi: 10.3389/fimmu.2023.1275372. eCollection 2023.
5
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.心脏淀粉样变性的治疗现状与未来方向及预后
Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.
6
Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.淀粉样变性治疗模式的转变：从疾病修饰药物到抗淀粉样纤维治疗。
Front Cardiovasc Med. 2022 Dec 20;9:1073503. doi: 10.3389/fcvm.2022.1073503. eCollection 2022.
7
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: State-of-the-Art Review.心脏病专家的AL淀粉样变性：认识、诊断及未来展望：最新综述
JACC CardioOncol. 2022 Nov 15;4(4):427-441. doi: 10.1016/j.jaccao.2022.08.009. eCollection 2022 Nov.
8
AL amyloidosis: untangling new therapies.AL 型淀粉样变：解开新疗法的谜团。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):682-688. doi: 10.1182/hematology.2021000305.
9
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.达雷妥尤单抗联合CyBorD方案用于新诊断的轻链型（AL）淀粉样变性患者。
Ther Adv Hematol. 2021 Nov 23;12:20406207211058334. doi: 10.1177/20406207211058334. eCollection 2021.
10
Current Updates on the Management of AL Amyloidosis.AL淀粉样变性病管理的最新进展
J Hematol. 2021 Aug;10(4):147-161. doi: 10.14740/jh866. Epub 2021 Aug 4.